378 related articles for article (PubMed ID: 11008125)
1. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
Meschler JP; Kraichely DM; Wilken GH; Howlett AC
Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of SR141716A on G-protein activation in rat brain.
Sim-Selley LJ; Brunk LK; Selley DE
Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
[TBL] [Abstract][Full Text] [Related]
3. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
5. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
6. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
[TBL] [Abstract][Full Text] [Related]
7. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.
Mato S; Pazos A; Valdizán EM
Eur J Pharmacol; 2002 May; 443(1-3):43-6. PubMed ID: 12044790
[TBL] [Abstract][Full Text] [Related]
9. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
Calandra B; Portier M; Kernéis A; Delpech M; Carillon C; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 1999 Jun; 374(3):445-55. PubMed ID: 10422789
[TBL] [Abstract][Full Text] [Related]
10. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
Ihenetu K; Molleman A; Parsons ME; Whelan CJ
Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).
Francisco ME; Seltzman HH; Gilliam AF; Mitchell RA; Rider SL; Pertwee RG; Stevenson LA; Thomas BF
J Med Chem; 2002 Jun; 45(13):2708-19. PubMed ID: 12061874
[TBL] [Abstract][Full Text] [Related]
13. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
15. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
Petitet F; Jeantaud B; Capet M; Doble A
Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
20. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
Nieri P; Martinotti E; Testai L; Adinolfi B; Calderone V; Breschi MC
Eur J Pharmacol; 2003 Jan; 459(1):75-81. PubMed ID: 12505536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
